180 related articles for article (PubMed ID: 33144509)
1. Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer.
Vassel FM; Bian K; Walker GC; Hemann MT
Proc Natl Acad Sci U S A; 2020 Nov; 117(46):28922-28924. PubMed ID: 33144509
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J
J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014
[TBL] [Abstract][Full Text] [Related]
3. REV7 is essential for DNA damage tolerance via two REV3L binding sites in mammalian DNA polymerase ζ.
Tomida J; Takata K; Lange SS; Schibler AC; Yousefzadeh MJ; Bhetawal S; Dent SY; Wood RD
Nucleic Acids Res; 2015 Jan; 43(2):1000-11. PubMed ID: 25567983
[TBL] [Abstract][Full Text] [Related]
4. A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy.
Wojtaszek JL; Chatterjee N; Najeeb J; Ramos A; Lee M; Bian K; Xue JY; Fenton BA; Park H; Li D; Hemann MT; Hong J; Walker GC; Zhou P
Cell; 2019 Jun; 178(1):152-159.e11. PubMed ID: 31178121
[TBL] [Abstract][Full Text] [Related]
5. Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells.
Niimi K; Murakumo Y; Watanabe N; Kato T; Mii S; Enomoto A; Asai M; Asai N; Yamamoto E; Kajiyama H; Shibata K; Kikkawa F; Takahashi M
Cancer Sci; 2014 May; 105(5):545-52. PubMed ID: 24597627
[TBL] [Abstract][Full Text] [Related]
6. Identification of the first small-molecule inhibitor of the REV7 DNA repair protein interaction.
Actis ML; Ambaye ND; Evison BJ; Shao Y; Vanarotti M; Inoue A; McDonald ET; Kikuchi S; Heath R; Hara K; Hashimoto H; Fujii N
Bioorg Med Chem; 2016 Sep; 24(18):4339-4346. PubMed ID: 27448776
[TBL] [Abstract][Full Text] [Related]
7. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
[TBL] [Abstract][Full Text] [Related]
8. Co-inhibition of Pol η and ATR sensitizes cisplatin-resistant non-small cell lung cancer cells to cisplatin by impeding DNA damage repair.
Li XQ; Ren J; Chen P; Chen YJ; Wu M; Wu Y; Chen K; Li J
Acta Pharmacol Sin; 2018 Aug; 39(8):1359-1372. PubMed ID: 29849128
[TBL] [Abstract][Full Text] [Related]
9. Human Pol ζ purified with accessory subunits is active in translesion DNA synthesis and complements Pol η in cisplatin bypass.
Lee YS; Gregory MT; Yang W
Proc Natl Acad Sci U S A; 2014 Feb; 111(8):2954-9. PubMed ID: 24449906
[TBL] [Abstract][Full Text] [Related]
10. A PolH Transcript with a Short 3'UTR Enhances PolH Expression and Mediates Cisplatin Resistance.
Zhang J; Sun W; Ren C; Kong X; Yan W; Chen X
Cancer Res; 2019 Jul; 79(14):3714-3724. PubMed ID: 31064846
[TBL] [Abstract][Full Text] [Related]
11. Co-inhibition of pol θ and HR genes efficiently synergize with cisplatin to suppress cisplatin-resistant lung cancer cells survival.
Dai CH; Chen P; Li J; Lan T; Chen YC; Qian H; Chen K; Li MY
Oncotarget; 2016 Oct; 7(40):65157-65170. PubMed ID: 27533083
[TBL] [Abstract][Full Text] [Related]
12. REV1 inhibitor JH-RE-06 enhances tumor cell response to chemotherapy by triggering senescence hallmarks.
Chatterjee N; Whitman MA; Harris CA; Min SM; Jonas O; Lien EC; Luengo A; Vander Heiden MG; Hong J; Zhou P; Hemann MT; Walker GC
Proc Natl Acad Sci U S A; 2020 Nov; 117(46):28918-28921. PubMed ID: 33168727
[TBL] [Abstract][Full Text] [Related]
13. REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells.
Wang W; Sheng W; Yu C; Cao J; Zhou J; Wu J; Zhang H; Zhang S
Oncol Rep; 2015 Sep; 34(3):1460-8. PubMed ID: 26165320
[TBL] [Abstract][Full Text] [Related]
14. A missense mutation in Rev7 disrupts formation of Polζ, impairing mouse development and repair of genotoxic agent-induced DNA lesions.
Khalaj M; Abbasi A; Yamanishi H; Akiyama K; Wakitani S; Kikuchi S; Hirose M; Yuzuriha M; Magari M; Degheidy HA; Abe K; Ogura A; Hashimoto H; Kunieda T
J Biol Chem; 2014 Feb; 289(6):3811-24. PubMed ID: 24356953
[TBL] [Abstract][Full Text] [Related]
15. Rev7, the regulatory subunit of Polζ, undergoes UV-induced and Cul4-dependent degradation.
Bhat A; Qin Z; Wang G; Chen W; Xiao W
FEBS J; 2017 Jun; 284(12):1790-1803. PubMed ID: 28440919
[TBL] [Abstract][Full Text] [Related]
16. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling.
Wang N; Song L; Xu Y; Zhang L; Wu Y; Guo J; Ji W; Li L; Zhao J; Zhang X; Zhan L
EBioMedicine; 2019 Sep; 47():65-77. PubMed ID: 31495720
[TBL] [Abstract][Full Text] [Related]
17. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
[TBL] [Abstract][Full Text] [Related]
18. Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy.
Doles J; Oliver TG; Cameron ER; Hsu G; Jacks T; Walker GC; Hemann MT
Proc Natl Acad Sci U S A; 2010 Nov; 107(48):20786-91. PubMed ID: 21068376
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of DNA polymerase ζ relieved the chemoresistance of glioma via inhibiting the PI3K/AKT signaling pathway.
Yang J; Ding W; Wang X; Xiang Y
Bioengineered; 2021 Dec; 12(1):3924-3933. PubMed ID: 34281455
[TBL] [Abstract][Full Text] [Related]
20. Roles of mutagenic translesion synthesis in mammalian genome stability, health and disease.
Jansen JG; Tsaalbi-Shtylik A; de Wind N
DNA Repair (Amst); 2015 May; 29():56-64. PubMed ID: 25655219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
